Dr Reddy's Labs Q1 PAT seen up 34% to Rs 281 cr
Dr Reddy's Labs is expected to report a 34% rise in its first quarter FY12 profit after tax to Rs 281 crore against Rs 209.6 crore in the year ago period, as per IFRS.
July 19, 2011 / 17:30 IST
Dr Reddy's Labs is expected to report a 34% rise in its first quarter FY12 profit after tax to Rs 281 crore against Rs 209.6 crore in the year ago period, as per IFRS.
Revenues are seen going up by 19% to Rs 2,005 crore from Rs 1,683 crore year-on-year, according to CNBC-TV18 poll.EBITDA is likely to go up by 28% to Rs 363 crore from Rs 262.5 crore year-on-year. Operating profit margin is seen improving at 18% versus 15.6%.Watch out for: -Revenues led by global generics segment and within that to be led by Russia/CIS. North America is expected to slow due to switch of Allegra to OTC (USD 20-25 million contribution in Q4). However Tacrolimus, Lansoprazole and Omeprazole OTC will contribute to growth in the US
o Q4 global generics revenues went up 37% to Rs 1416 crore; revenues from America jumped 69% to Rs 591 crore & Russia/CIS went up 26% to Rs 200 crore
-Betapharm may improve on topline due to tender business picking up
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
